Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 4/20 | 0.59 |
| ▸ | MAX | P61244 | 4/20 | 0.59 |
| ▸ | BCL2 | P10415 | 1/20 | 0.55 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.55 |
| ▸ | EP300 | Q09472 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | PELP1 | Q8IZL8 | 1/20 | 0.48 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | TOP2A | P11388 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16369623 | 0.89 | BCL2 (0.62) | MYCMAXBCL2BCL2L1MCL1 | |
| SCHEMBL16392512 | 0.85 | EP300 (0.66) | MYCMAXEP300HIF1AAR | |
| SCHEMBL16369611 | 0.84 | BCL2 (0.69) | MYCMAXBCL2BCL2L1MCL1 | |
| SCHEMBL16392472 | 0.82 | BCL2 (0.68) | MYCMAXBCL2BCL2L1MCL1 | |
| SCHEMBL4651409 | 0.81 | MYC (0.59) | MYCMAXBCL2BCL2L1MCL1 | |
| SCHEMBL4653661 | 0.81 | MYC (0.59) | MYCMAXBCL2BCL2L1MCL1 | |
| SCHEMBL17795677 | 0.80 | EP300 (0.53) | MYCMAXEP300HIF1AAR | |
| SCHEMBL16392556 | 0.79 | EP300 (0.52) | MYCMAXEP300HIF1AAR | |
| SCHEMBL17795679 | 0.77 | EP300 (0.50) | MYCMAXEP300HIF1AAR | |
| SCHEMBL17795676 | 0.77 | EP300 (0.52) | MYCMAXEP300HIF1AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225503-B2 | Crystobactamides | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2022-01-18 | — | — | US | disclosed |
| US-11225503-B2 | Crystobactamides | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2022-01-18 | — | — | US | disclosed |
| EP-3019615-B1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2021-04-07 | — | — | EP | disclosed |
| CN-105793424-B | Ascomycetes amides | 亥姆霍兹感染研究中心有限公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20200331964-A1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2020-10-22 | — | — | US | disclosed |
| US-20200331964-A1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2020-10-22 | — | — | US | disclosed |
| US-10793600-B2 | Cystobactamides | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-10793600-B2 | Cystobactamides | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-20190185514-A1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| US-20190185514-A1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
| US-20160145304-A1 | CYSTOBACTAMIDES | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20160145304-A1 | CYSTOBACTAMIDES | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2016-05-26 | — | — | US | disclosed |
| EP-3019615-A2 | CYSTOBACTAMIDES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015003816-A2 | CYSTOBACTAMIDES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015003816-A2 | CYSTOBACTAMIDES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145304-A1 | CYSTOBACTAMIDES | CTH, SLC7A11, CBS | MYC 2363/4885MAX 3953/4885BCL2 2186/4885 |
| US-11225503-B2 | Crystobactamides | PKD2, SLC7A11, CTH | MYC 3391/4885MAX 4641/4885BCL2 2103/4885 |
| US-20190185514-A1 | CYSTOBACTAMIDES | CTH, SLC7A11, SULT2A1 | MYC 3303/4885MAX 4549/4885BCL2 3703/4885 |
| US-20200331964-A1 | CYSTOBACTAMIDES | CTH, SLC7A11, SULT2A1 | MYC 3082/4885MAX 4540/4885BCL2 3481/4885 |
| US-10793600-B2 | Cystobactamides | CTH, SLC7A11, SULT2A1 | MYC 3574/4885MAX 4624/4885BCL2 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.